Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in Post-infection IBS
NCT05461833Completed
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, open-label trial of Fecal Microbiota Transplantation Capsule in irritable bowel syndrome (IBS) (2 arms). Primary endpoints: Irritable Bowel Syndrome Severity Scoring System at 12 weeks and Response Rate at 12 weeks. Started Sep 2020; status: completed.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT05461833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05461833.